Neurol. praxi. 2019;20(2):131-135 | DOI: 10.36290/neu.2019.101
Teriflunomide in treating clinically isolated syndrome
- Neurologické oddělení Nemocnice Jihlava
Teriflunomide is the only oral drug that can be used to commence treatment in patients after the initial demyelinating event. The TOPIC clinical trial dealt with patients with clinically isolated syndrome. The primary objective of the trial was the time to second relapse which also meant conversion of the disease to definite multiple sclerosis. The group treated with teriflunomide at a dose of 14 mg daily achieved a reduction in the risk of a further relapse by 42.6% compared with the placebo group. The present case report documents our experience with teriflunomide treatment in a female patient with clinically isolated syndrome. The patient had no relapses during three years of treatment, with no progression of disability and a stable finding on magnetic resonance imaging.
Keywords: multiple sclerosis, clinically isolated syndrome, teriflunomide
Published: April 23, 2019 Show citation
References
- Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014; 74(6): 659-674.
Go to original source... - Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L and TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(3): 247-256. Go to original source...
- Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW and TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(10): 977-986. Go to original source...
- Miller AE. Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience. Ther Adv Neurol Disord. 2017; 10(12): 381-396. Go to original source...
Go to PubMed... - Montalban X, Sastre-Gariga J. Diagnosis and trials of clinically isolated syndrome. Lancet Neurol. 2014; 13(10):962-963. Go to original source...
- Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing - Remitting Multiple Sclerosis. Adv Ther 2014; 31: 1134-1154. Go to original source...
- O'Connor P, Wolinsky JS, Confavreux CH, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS and TEMSO Trial Group. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. N Engl J Med 2011; 365: 1293-1303. Go to original source... Go to PubMed...
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292-302. Go to original source...
- Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162-173. Go to original source...
- Thrower BW. Clinically isolated syndromes, predicting and delaying multiple sclerosis. Neurology. June 12, 2007; 68 (24 suppl 4). Go to original source... Go to PubMed...
- Yamout B, Al Khawajah M. Radiologically isolated syndrome and multiple sclerosis. Mult Scler Relat Disord. 2017; 17: 234-237. Go to original source... Go to PubMed...